Quadrant 2™: Predictive Platform For Solubility And Bioavailability Enhancement

Poor solubility affects approximately 80% of drug molecules in development, and the traditional response, iterative trial-and-error screening, can consume 14 to 19 months of your timeline before you land on a workable formulation approach. For teams managing constrained resources and competitive development schedules, that delay is costly in more ways than one: post-proof-of-concept reformulation setbacks alone can add up to 12 months and $500,000 to $600,000 in avoidable spend.

Thermo Fisher Scientific's Quadrant 2 platform takes a fundamentally different approach. By combining AI and machine learning with in silico modeling technologies including quantum mechanics, molecular dynamics, QSAR, and ADMET, the platform analyzes your compound's molecular structure alongside your target product profile to predict the most effective solubility enhancement strategy before any lab work begins.

The results speak for themselves. Validation studies confirm that the technology-selection tool exceeds 90% accuracy, while the excipient-selection tool achieves over 80% accuracy. With more than 400 molecules analyzed and 300-plus customers served, this platform delivers a comprehensive formulation recommendation within two weeks of your initial consultation.

Whether your molecule requires solid dispersions, cyclodextrins, lipid-based systems, or size reduction, you get a clear, data-driven path forward rather than an open-ended screening exercise. Download the overview now to see how Thermo Fisher Scientific's Quadrant 2 platform can accelerate your formulation strategy and protect your development timeline.